Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  San Francisco
US -  Boston

GLOBAL

English

SOLUTIONS

RESOURCES

ABOUT US

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  San Francisco
US -  Boston

GLOBAL

English

Novotech CRO at 2019 KoNECT-MOHW-MFDS International Conference, Seoul, South Korea

Novotech CRO at 2019 KoNECT-MOHW-MFDS International Conference, Seoul, South Korea

September 17,2019

Seoul, South Korea – Award-winning Asia-Pacific specialist CRO Novotechwill attend the 2019 KoNECT conference in Seoul, South Korea this week (Booth #15).

The Novotech CRO South Korea team will attend the conference to meet with local and international biotechs and the local clinical community.

Novotech is the leading and most experienced CRO in the region with a track-record in Asia-Pacific clinical trials spanning 23 years.

KoNECT is a one-of-a-kind conference on clinical trials in Asia, and is co-hosted by Ministry of Food and Drug Safety and supported by Ministry of Health and Welfare. 

Novotech CEO Dr John Moller said:

“Novotech has recently welcomed the South Korean Government’s 5-year Plan to further support and speed-up approvals for biotech clinical trials, because it will attract more of Novotech’s US biotech clients to South Korea which already has an outstanding clinical reputation.”

The Asia-Pacific is in high-demand for biotech clinical research:

“A global migration of clinical research is occurring from high-income countries to low and middle-income countries with emerging economies. Over the period 2017 to 2018, for example, the number of clinical trial sites opened by biotech companies in Asia-Pacific increased by 35% compared to 8% in the rest of the world…” (source GlobalData)